Danaher (DHR)
(Real Time Quote from BATS)
$274.93 USD
+1.78 (0.65%)
Updated Sep 24, 2024 10:40 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Company Summary
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. It is headquartered in Washington, DC.
On a geographical basis, the company has operations in the North America (47% of 2023 net revenues), Western Europe (16%), other developed markets (5%) and high-growth markets (32%). Exiting 2023, it has an employee base of 63,000 people. The company’s segmental details are provided below:
Diagnostics segment (40.1% of revenues generated in 2023) offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps ...
Company Summary
On a geographical basis, the company has operations in the North America (47% of 2023 net revenues), Western Europe (16%), other developed markets (5%) and high-growth markets (32%). Exiting 2023, it has an employee base of 63,000 people. The company’s segmental details are provided below:
Diagnostics segment (40.1% of revenues generated in 2023) offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps diagnose diseases and make suitable treatment decisions. Leica Biosystems, a medical devices unit within the segment, develops and supplies clinical diagnostics to the pathology market. Another unit, Beckman Colter, manufactures and sells products relevant to biomedical testing.
Life Sciences segment (29.9%) provides a broad range of research tools used to analyze a range of critical areas — including genes, proteins, metabolites and cells — to understand the causes of diseases, identify new therapies and test new drugs and vaccines. The range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial. In addition, the segment offers products and consumables that are designed to filter and remove contaminants from various liquids and gases in several end-market applications.
Biotechnology segment (30%) includes bioprocessing and discovery and medical businesses. It provides a wide range of tools, consumables and services utilized in the research, development, manufacturing and delivery process of biological medicines. The company’s solutions support biotherapeutics that range from replacement therapies like vaccines, insulin, recombinant proteins and other biological drugs to mRNA, novel cell, gene and other nucleic acid therapies.
In September 2023, the company spun off its Environmental & Applied Solutions segment into an independent public company. The separation helps Danaher focus more on its core Life Sciences and Biotechnology segments.
General Information
Danaher Corporation
2200 PENNSYLVANIA AVE. N.W SUITE 800W
WASHINGTON, DC 20037
Phone: 202-828-0850
Fax: 202-828-0860
Email: investor.relations@danaher.com
Industry | Diversified Operations |
Sector | Conglomerates |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Earnings Date | 10/22/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.56 |
Current Year EPS Consensus Estimate | 7.59 |
Estimated Long-Term EPS Growth Rate | 7.90 |
Earnings Date | 10/22/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 273.15 |
52 Week High | 281.70 |
52 Week Low | 182.09 |
Beta | 0.83 |
20 Day Moving Average | 2,641,849.50 |
Target Price Consensus | 288.83 |
4 Week | 1.89 |
12 Week | 11.71 |
YTD | 18.07 |
4 Week | 0.08 |
12 Week | 6.96 |
YTD | -1.52 |
Shares Outstanding (millions) | 722.21 |
Market Capitalization (millions) | 197,272.50 |
Short Ratio | NA |
Last Split Date | 6/14/2010 |
Dividend Yield | 0.40% |
Annual Dividend | $1.08 |
Payout Ratio | 0.14 |
Change in Payout Ratio | 0.02 |
Last Dividend Payout / Amount | 6/28/2024 / $0.27 |
Fundamental Ratios
P/E (F1) | 35.98 |
Trailing 12 Months | 35.24 |
PEG Ratio | 4.55 |
vs. Previous Year | -16.10% |
vs. Previous Quarter | -10.42% |
vs. Previous Year | -19.76% |
vs. Previous Quarter | -0.91% |
Price/Book | 3.95 |
Price/Cash Flow | 25.78 |
Price / Sales | 7.95 |
6/30/24 | 11.06 |
3/31/24 | 11.43 |
12/31/23 | 12.25 |
6/30/24 | 6.93 |
3/31/24 | 7.09 |
12/31/23 | 7.43 |
6/30/24 | 1.43 |
3/31/24 | 1.85 |
12/31/23 | 1.68 |
6/30/24 | 1.04 |
3/31/24 | 1.51 |
12/31/23 | 1.37 |
6/30/24 | 23.33 |
3/31/24 | 23.00 |
12/31/23 | 23.02 |
6/30/24 | 16.94 |
3/31/24 | 16.78 |
12/31/23 | 17.26 |
6/30/24 | 19.07 |
3/31/24 | 18.27 |
12/31/23 | 21.11 |
6/30/24 | 69.10 |
3/31/24 | 72.16 |
12/31/23 | 72.39 |
6/30/24 | 3.51 |
3/31/24 | 3.45 |
12/31/23 | 3.24 |
6/30/24 | 0.33 |
3/31/24 | 0.31 |
12/31/23 | 0.31 |
6/30/24 | 24.63 |
3/31/24 | 23.50 |
12/31/23 | 23.80 |